PMID- 19910746
OWN - NLM
STAT- MEDLINE
DCOM- 20091207
LR  - 20210108
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 88
IP  - 6
DP  - 2009 Nov
TI  - Influence of lymphocyte recovery on outcome of haploidentical transplantation for 
      hematologic malignancies.
PG  - 322-330
LID - 10.1097/MD.0b013e3181c167e2 [doi]
AB  - Unmanipulated human leukocyte antigen (HLA)-mismatched/haploidentical blood and 
      marrow transplantation is an established treatment for patients without 
      HLA-matched related or unrelated donors. However, the prognostic significance of 
      early lymphocyte recovery in this transplant setting is not defined. In this 
      study, we investigated the association of day 30 absolute lymphocyte count 
      (ALC-30) with outcome after unmanipulated HLA-mismatched/haploidentical 
      transplantation. We prospectively analyzed the relationship between ALC-30 and 
      transplant outcomes in 206 patients with hematologic malignancies receiving 
      T-cell-replete transplantation from HLA-mismatched/haploidentical related donors. 
      Multivariate analysis showed that ALC-30 above the cutoff value of 300 
      cells/microL was associated with improved overall survival (hazard ratio [HR], 
      0.258; 95% confidence interval [CI], 0.141-0.472; p < 0.0001); improved 
      cancer-free survival (HR, 0.289; 95% CI, 0.166-0.501; p < 0.0001); reduced 
      relapse (HR, 0.370; 95% CI, 0.161-0.853; p = 0.020); and decreased 
      transplant-related mortality (HR, 0.211; 95% CI, 0.097-0.457; p < 0.0001). Our 
      results suggest that the recovery of ALC-30 might have an influence on transplant 
      outcomes following unmanipulated HLA-mismatched/haploidentical transplantation.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - From Peking University People's Hospital (YJC, XYZ, MRH, LPX, DHL, KYL, XJH), 
      Peking University Institute of Hematology, Beijing; and Department of Hematology 
      (YJC), Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Zhao, Xiang-Yu
AU  - Zhao XY
FAU - Huo, Ming-Rui
AU  - Huo MR
FAU - Xu, Lan-Ping
AU  - Xu LP
FAU - Liu, Dai-Hong
AU  - Liu DH
FAU - Liu, Kai-Yan
AU  - Liu KY
FAU - Huang, Xiao-Jun
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Cyclosporine/therapeutic use
MH  - Female
MH  - Graft vs Host Disease/prevention & control
MH  - HLA Antigens/immunology
MH  - Haplotypes
MH  - Hematologic Neoplasms/*immunology/surgery
MH  - *Hematopoietic Stem Cell Transplantation/mortality
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - *Lymphocyte Count
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/11/17 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/11/14 06:00
PHST- 2009/11/14 06:00 [entrez]
PHST- 2009/11/17 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 00005792-200911000-00002 [pii]
AID - 10.1097/MD.0b013e3181c167e2 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2009 Nov;88(6):322-330. doi: 10.1097/MD.0b013e3181c167e2.